Last reviewed · How we verify
Pegylated rhEPO — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Pegylated rhEPO (Pegylated rhEPO) — Xiamen Amoytop Biotech Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pegylated rhEPO TARGET | Pegylated rhEPO | Xiamen Amoytop Biotech Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pegylated rhEPO CI watch — RSS
- Pegylated rhEPO CI watch — Atom
- Pegylated rhEPO CI watch — JSON
- Pegylated rhEPO alone — RSS
Cite this brief
Drug Landscape (2026). Pegylated rhEPO — Competitive Intelligence Brief. https://druglandscape.com/ci/pegylated-rhepo. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab